Compared with other metastatic sites, breast cancer brain metastases (BCBMs) are associated with the shortest survival time. In addition, human epidermal growth factor receptor 2 (HER2) is observed to be amplified in 20-25% of breast cancer cases where it is a poor prognostic factor for brain metastases. Various anti-HER2 targeted therapies have brought both new opportunities and challenges to patients with HER2-positive BCBM over the past decade. However, prolonging survival time and improving quality of life of patients have become controversial issues in the field of clinical research on BCBMs. On the basis of the latest literature, the present review documents the anti-HER2 targeted drugs applied in patients with HER2-positive BCBM. Further studies on the efficacy and safety of novel HER2-targeted drugs and combined or sequential therapy in clinical treatment are expected to provide more effective strategies for the treatment of patients with HER2-positive BCBM.
基金：
Outstanding Young Scientific and Technological Talents Fund of Sichuan Province [2022JDJQ0059]; National Natural Science Foundation of China [82003198, 82270196]
第一作者机构：[1]Univ Elect Sci & Technol China, Sichuan Canc Hosp & Inst, Sichuan Clin Res Ctr Canc, Dept Med Oncol,Sichuan Canc Ctr,Sch Med, 55 Sect 4 South Renmin Rd, Chengdu 610041, Sichuan, Peoples R China
通讯作者：
推荐引用方式(GB/T 7714)：
Wang Zhangyan,Hong Huangming.Anti-HER2-targeted therapies for the treatment of advanced HER2-positive breast cancer with brain metastases (Review)[J].MOLECULAR AND CLINICAL ONCOLOGY.2025,22(5):45.doi:10.3892/mco.2025.2840.
APA：
Wang, Zhangyan&Hong, Huangming.(2025).Anti-HER2-targeted therapies for the treatment of advanced HER2-positive breast cancer with brain metastases (Review).MOLECULAR AND CLINICAL ONCOLOGY,22,(5)
MLA：
Wang, Zhangyan,et al."Anti-HER2-targeted therapies for the treatment of advanced HER2-positive breast cancer with brain metastases (Review)".MOLECULAR AND CLINICAL ONCOLOGY 22..5(2025):45
